Research Programme: capridines - AV Therapeutics

Drug Profile

Research Programme: capridines - AV Therapeutics

Alternative Names: BIO 131; C-1748; Capridine; Capridine-beta; INOC 005

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator New York Medical College
  • Developer AV Therapeutics
  • Class Nitrogen compounds
  • Mechanism of Action Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Prostate cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Prostate-cancer in USA
  • 13 Feb 2014 Research Programme: capridine-beta is available for licensing as of 13 Feb 2014. http://www.avtherapeutics.com/company.html
  • 05 Feb 2014 AV Therapeutics enters into a Good Manufacturing Practices agreement for capridine synthesis with DavosPharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top